SG11202011680YA - Dosing regimen for the treatment of pi3k related disorders - Google Patents
Dosing regimen for the treatment of pi3k related disordersInfo
- Publication number
- SG11202011680YA SG11202011680YA SG11202011680YA SG11202011680YA SG11202011680YA SG 11202011680Y A SG11202011680Y A SG 11202011680YA SG 11202011680Y A SG11202011680Y A SG 11202011680YA SG 11202011680Y A SG11202011680Y A SG 11202011680YA SG 11202011680Y A SG11202011680Y A SG 11202011680YA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- related disorders
- dosing regimen
- pi3k related
- pi3k
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679556P | 2018-06-01 | 2018-06-01 | |
| US201862714448P | 2018-08-03 | 2018-08-03 | |
| US201862773612P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/034613 WO2019232188A1 (en) | 2018-06-01 | 2019-05-30 | Dosing regimen for the treatment of pi3k related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011680YA true SG11202011680YA (en) | 2020-12-30 |
Family
ID=67003653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011680YA SG11202011680YA (en) | 2018-06-01 | 2019-05-30 | Dosing regimen for the treatment of pi3k related disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190365764A1 (en) |
| EP (1) | EP3801533A1 (en) |
| JP (1) | JP7455763B2 (en) |
| KR (1) | KR20210018328A (en) |
| CN (1) | CN112469418A (en) |
| AU (1) | AU2019277560A1 (en) |
| BR (1) | BR112020024427A2 (en) |
| CA (1) | CA3101323A1 (en) |
| CL (1) | CL2020003118A1 (en) |
| EC (1) | ECSP20077106A (en) |
| IL (1) | IL278889A (en) |
| MA (1) | MA52761A (en) |
| MX (1) | MX2020012826A (en) |
| PE (1) | PE20211208A1 (en) |
| PH (1) | PH12020552059A1 (en) |
| SG (1) | SG11202011680YA (en) |
| TW (1) | TW202015693A (en) |
| WO (1) | WO2019232188A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087760A1 (en) | 2011-09-02 | 2014-04-16 | Incyte Corp | HETEROCICLILAMINAS AS PI3K INHIBITORS |
| TWI736135B (en) * | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS |
| US20210253582A1 (en) * | 2020-02-06 | 2021-08-19 | Incyte Corporation | Salts and solid forms and processes of preparing a pi3k inhibitor |
| AR127966A1 (en) | 2021-12-16 | 2024-03-13 | Incyte Corp | TOPICAL FORMULATIONS OF PI3K-DELTA INHIBITORS |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1294358E (en) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | MOORING PROCESS BY HUMIDITY |
| US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| AU2010273816B2 (en) | 2009-06-29 | 2015-07-09 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
| US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2011075630A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| KR102354472B1 (en) | 2010-03-10 | 2022-01-21 | 인사이트 홀딩스 코포레이션 | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| JP5917544B2 (en) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| JP5876146B2 (en) | 2011-06-20 | 2016-03-02 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Azetidinylphenyl, pyridyl, or pyrazinylcarboxamide derivatives as JAK inhibitors |
| TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
| AR087760A1 (en) | 2011-09-02 | 2014-04-16 | Incyte Corp | HETEROCICLILAMINAS AS PI3K INHIBITORS |
| AR091079A1 (en) | 2012-05-18 | 2014-12-30 | Incyte Corp | DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS |
| TWI736135B (en) * | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS |
| PT3262046T (en) * | 2015-02-27 | 2020-12-24 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
-
2019
- 2019-05-30 MA MA052761A patent/MA52761A/en unknown
- 2019-05-30 JP JP2020566893A patent/JP7455763B2/en active Active
- 2019-05-30 WO PCT/US2019/034613 patent/WO2019232188A1/en unknown
- 2019-05-30 PE PE2020001922A patent/PE20211208A1/en unknown
- 2019-05-30 EP EP19733240.6A patent/EP3801533A1/en active Pending
- 2019-05-30 CA CA3101323A patent/CA3101323A1/en active Pending
- 2019-05-30 KR KR1020207037699A patent/KR20210018328A/en unknown
- 2019-05-30 AU AU2019277560A patent/AU2019277560A1/en active Pending
- 2019-05-30 SG SG11202011680YA patent/SG11202011680YA/en unknown
- 2019-05-30 MX MX2020012826A patent/MX2020012826A/en unknown
- 2019-05-30 BR BR112020024427-9A patent/BR112020024427A2/en unknown
- 2019-05-30 CN CN201980048918.4A patent/CN112469418A/en active Pending
- 2019-05-31 TW TW108118995A patent/TW202015693A/en unknown
- 2019-05-31 US US16/428,056 patent/US20190365764A1/en active Pending
-
2020
- 2020-11-22 IL IL278889A patent/IL278889A/en unknown
- 2020-11-30 CL CL2020003118A patent/CL2020003118A1/en unknown
- 2020-11-30 EC ECSENADI202077106A patent/ECSP20077106A/en unknown
- 2020-12-01 PH PH12020552059A patent/PH12020552059A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020003118A1 (en) | 2021-04-30 |
| US20190365764A1 (en) | 2019-12-05 |
| BR112020024427A2 (en) | 2021-03-23 |
| AU2019277560A1 (en) | 2020-12-10 |
| JP2021525757A (en) | 2021-09-27 |
| JP7455763B2 (en) | 2024-03-26 |
| KR20210018328A (en) | 2021-02-17 |
| PH12020552059A1 (en) | 2021-07-05 |
| EP3801533A1 (en) | 2021-04-14 |
| PE20211208A1 (en) | 2021-07-05 |
| TW202015693A (en) | 2020-05-01 |
| MX2020012826A (en) | 2021-03-09 |
| CN112469418A (en) | 2021-03-09 |
| IL278889A (en) | 2021-01-31 |
| ECSP20077106A (en) | 2021-01-29 |
| MA52761A (en) | 2021-04-14 |
| CA3101323A1 (en) | 2019-12-05 |
| WO2019232188A1 (en) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| HK1251257A1 (en) | Use of exosomes for the treatment of disease | |
| EP3618829C0 (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| IL253945B (en) | Kdm1a inhibitors for the treatment of disease | |
| FI3936130T3 (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| IL276398A (en) | Combination therapy for the treatment of mastocytosis | |
| IL278889A (en) | Dosing regimen for the treatment of pi3k related disorders | |
| EP3634417C0 (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| IL279260A (en) | Kdm1a inhibitors for the treatment of disease | |
| IL275708A (en) | G1t38 superior dosage regimes | |
| IL283948A (en) | Methods for the treatment of depression | |
| SG10202107832UA (en) | Dosage regimen for treatment of solid tumors | |
| IL265762A (en) | Dosing regimen of avelumab for the treatment of cancer | |
| IL284175A (en) | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders | |
| PL3484475T3 (en) | 1-methylnicotinamide for the treatment of cardiovascular disease | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| FI3442537T3 (en) | (+)-azasetron for use in the treatment of ear disorders | |
| GB201614179D0 (en) | Dosage regimen for the treatment of endometriosis | |
| HUE058845T2 (en) | Non-bioconvertible c3-substituted pregnenolone derivatives for use in the treatment of substance use disorders | |
| GB201602248D0 (en) | Dosage regimen for the treatment of acute exacerbations of inflammatory conditions | |
| GB201602249D0 (en) | Dosage regimen for the treatment of acute exacerbations of inflammatory conditions | |
| PT3442537T (en) | (+)-azasetron for use in the treatment of ear disorders |